Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 445

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 3
Chunk 445
---
ensed during the period ended June 30, 2024. These costs
are included in “selling, general and administrative expenses” in the accompanying condensed consolidated statements of operations.

Consolidated unaudited pro forma information: 

The following consolidated pro forma information assumes that the acquisition
of GEDi took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have
been estimated after applying the Company’s accounting policies:

    F-34

    Revenues 
    $— 
  
    Net loss 
    $(83,571,822)

The unaudited pro forma results
are presented for informational purposes only and are not necessarily indicative of what the actual results of operations would have been
if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations.

NOTE 14 — SEGMENT REPORTING

For the year ended June 30, 2025,
the Company had three reportable segments. These segments have different strategic and economic goals and are managed separately because
they require different technology and marketing strategies.

Reportable
Segment
 
Description

RENB
 
Developing new immunotherapies
to combat cancer 

BioSymetrics
 
Integrating multimodal data
sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic
development, and precision medicine.

RENC
 
Developing a predicative artificial intelligence based
diagnostic methodology for the use of earlier cancer detection 

The Company’s
chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly.
During the year ended June 30, 2025, there were no significant inter-company revenues or expenses. The chief operating decision maker
assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on
the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets.
The accounting policies of each segment are the same as those described in the summary of significant accounting policies.

    Schedule of segment operating loss and
    asset information 

    Operating loss 
    Assets
  
    United States (RENB) 
    $15,530,056  
    $1,907,647 
  
    United States (BioSymetrics) 
     237,880  
     6,